Cerebrovascular reserve (CVR) is an important hemodynamic parameter for moyamoya disease. Acetazolamide (ACZ) test is often used to measure CVR clinically. However, ACZ is contraindicated in patients with sulfa allergies, severe kidney and liver disease and potentially has severe adverse side effect. Thus, there is a need to assess CVR without pharmacological vasodilation. We utilized a simultaneous [15O]-water PET/MRI dataset to train a convolutional neural network (CNN) to predict CVR. The CNN combined multi-contrast information from baseline perfusion and structural images to predict whole-brain PET-level CVR, with high image quality, quantification accuracy, and diagnostic accuracy for identifying impaired CVR.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords